Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health Plc LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00 -0.8% 247.00 29,462 13:18:18
Bid Price Offer Price High Price Low Price Open Price
247.00 248.50 251.00 246.00 250.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.86 -43.59 -15.53 711
Last Trade Time Trade Type Trade Size Trade Price Currency
13:16:55 AT 72 247.00 GBX

Puretech Health (PRTC) Latest News (1)

More Puretech Health News
Puretech Health Investors    Puretech Health Takeover Rumours

Puretech Health (PRTC) Discussions and Chat

Puretech Health Forums and Chat

Date Time Title Posts
07/2/202314:12PureTech Health - innovative healthcare1,551
22/7/201820:35PureTech Health (PRTC) One to Watch Monday -

Add a New Thread

Puretech Health (PRTC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Puretech Health trades in real-time

Puretech Health (PRTC) Top Chat Posts

Top Posts
Posted at 08/2/2023 08:20 by Puretech Health Daily Update
Puretech Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 249p.
Puretech Health Plc has a 4 week average price of 245.50p and a 12 week average price of 233.50p.
The 1 year high share price is 300p while the 1 year low share price is currently 145.80p.
There are currently 287,796,585 shares in issue and the average daily traded volume is 196,031 shares. The market capitalisation of Puretech Health Plc is £710,857,564.95.
Posted at 12/12/2022 16:05 by rogers49
Agree, PRTC should be a lot higher.
Posted at 09/12/2022 23:02 by rambutan2
Agree, I've always had high hopes for their tech.

Posted at 11/10/2022 07:15 by liam1om
So PRTC sees a large drop on offer talks. You would assume once offer talks were off the price rebounds?
Posted at 07/10/2022 11:38 by sspurt
It looks like a reverse takeover to me - I can't see any logic in PRTC selling out as they have a cash runway to at least 2026 and cash/liquid assets worth more than the current mkt cap so everything else is in for free. Nektar need rescuing probably I am guessing but our management team have some serious explaining to do if they are going to get our shareholders to agree to this proposal. Not seen any broker research, both PH and Lib silent as yet.
Posted at 07/10/2022 07:38 by 74tom
It's not mad at all, the market is pricing in a likely all-share deal because Nektar don't have the capital to buy PRTC outright...

Cash of ~$630m at 30/06 and they had burned through $160m in the prior 6 month period... PRTC has a market cap of $685m at 218p.. it's not difficult to do the maths and realise the offer will be in Nektar shares. Do big PRTC holders want to own Nektar shares? The answer appears to be no...

Posted at 07/10/2022 07:29 by deanmatlazin
i thought the offer should be £5/share at least and NOT £2/share. Are they having a laugh?
Posted at 22/8/2022 13:05 by rambutan2
So less cash raised than originally hoped for, as all SPAC cash was redeemed. But on the bright side, does mean that PRTC keeps hold of a bigger slice of what could be a nicely profitable pie:

The transaction implies a post-money equity value of the combined company of up to approximately $1 billion and is expected to deliver up to $412 million in gross cash proceeds to the Company, including the contribution of up to $250 million of cash held in SCS’s trust account and $162 million from PIPE investors at $10 per share. All references to available cash from the trust account and retained transaction proceeds are subject to any redemptions by the public shareholders of SCS and payment of transaction expenses. Akili plans to use the net proceeds to help fund the Company’s go-to-market strategy, to further advance its pipeline of prescription digital therapeutics targeting a range of chronic and acute cognitive disorders, and for other general corporate purposes.

Existing Akili shareholders will roll 100% of their equity into the combined company and will be eligible to receive additional SCS shares pursuant to an earnout based on the combined company’s future stock performance.Chamath Palihapitiya is expected to join Akili’s board of directors as chair, upon the close of the transaction.The proposed business combination, which has been unanimously approved by the boards of directors of both Akili and SCS, is expected to close in mid-2022, subject to approval by SCS’s and Akili’s shareholders, regulatory approvals, and other customary closing conditions.


Posted at 22/8/2022 08:07 by 74tom
“Following the closing of the business combination, PureTech holds 12,549,207 shares of Akili common stock“

Anyone spot that Akili went crazy after hours Friday hitting $40?! That would value PRTC’s holding at £425m / £1.50 a share… I presume PRTC will reduce their holding if big volume hits Akili today…

Posted at 19/5/2022 20:46 by deadly nightshade
It's strange the low buy back volumes every day, is that a sign that there is very few floating shares to buy? In which case it makes you wonder why the share price basically halved for a reason that I still can't fathom out. Really can't get my head around the markets these days it's really weird this can still be valued at a share price it was sitting at 3 year ago when we had nothing like the progress or cash on the balance sheet we have now. Why this is not on the radar of a large pharma for a takeout is beyond me this would be pocket money to some of the big companies to buy up
Posted at 04/6/2020 19:15 by lendmeafiver
what the PRTC Share Price?
Puretech Health share price data is direct from the London Stock Exchange
Your Recent History
Puretech H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230208 13:33:23